Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Drugs from the Sea
The present book consists of three parts: discovery, development and production of drugs from marine organisms. Marine bacteria, fungi, microalgae, sponges and opisthobranch mollusks have attracted much attention as sources of potential drugs, which is described in the first part. A pain-killing drug developed from the venom of a cone shell is a recent highlight of marine natural product research; the interesting story of its discovery is provided. The second part features an anticancer drug with a novel mode of action which was originally isolated from a songe and a potential antiosteoporotic drug of a hexacoral origin. But the most serious problem for development of drugs from the sea remains supply. Two possible solutions, production by fermentation and by aquaculture, are described in the third part. Identification and culture of symbiotic bacteria which are responsible for the production of bioactive sponge metabolites are the main objectives for many researchers.
T Cell Activation by CD1 and Lipid Antigens
There is increasing evidence that the CD1 system has been conserved throughout mammalian evolution and is capable of presenting structurally diverse diacyglycerol, sphingolipid, polyisoprenol and lipopeptide antigens. This volume provides a comprehensive discussion of these basic aspects of CD1 biology and summarizes the most recent research into the role of CD1 in infectious, autoimmune, allergic and neoplastic disease.
Tokyo Municipal News
None
Cutaneous Oncology and Skin Cancer Genomics
This Research Topic of Frontiers in Medicine is focused on the new diagnostic and therapeutic protocols in the field of skin (solid tumors and lymphoma) and soft tissue oncology with an emphasis on challenging, complex, and advanced clinical scenarios as follows; • patients presenting with numerous and or recurring skin and soft tissue malignancies. • immune deficiencies, including but not limited to organ transplant patients. • management of patients with adverse events due to underlying oncological treatments such as life-saving clinical trials or treatment protocols. • describing the cutaneous adverse events of emerging oncological treatment not yet reported in the literature. •...
Acta Asiatica
None
